8-72026097-G-C
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The ENST00000262209.5(TRPA1):c.2938-24C>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.259 in 1,575,902 control chromosomes in the GnomAD database, including 54,975 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.22 ( 4181 hom., cov: 32)
Exomes 𝑓: 0.26 ( 50794 hom. )
Consequence
TRPA1
ENST00000262209.5 intron
ENST00000262209.5 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 2.01
Genes affected
TRPA1 (HGNC:497): (transient receptor potential cation channel subfamily A member 1) The structure of the protein encoded by this gene is highly related to both the protein ankyrin and transmembrane proteins. The specific function of this protein has not yet been determined; however, studies indicate the function may involve a role in signal transduction and growth control. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BP6
Variant 8-72026097-G-C is Benign according to our data. Variant chr8-72026097-G-C is described in ClinVar as [Benign]. Clinvar id is 1342277.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.333 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TRPA1 | NM_007332.3 | c.2938-24C>G | intron_variant | ENST00000262209.5 | NP_015628.2 | |||
MSC-AS1 | NR_033652.1 | n.1029-26442G>C | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TRPA1 | ENST00000262209.5 | c.2938-24C>G | intron_variant | 1 | NM_007332.3 | ENSP00000262209 | P1 | |||
MSC-AS1 | ENST00000518916.5 | n.392-26442G>C | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.224 AC: 34143AN: 152108Hom.: 4180 Cov.: 32
GnomAD3 genomes
AF:
AC:
34143
AN:
152108
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.252 AC: 62748AN: 249216Hom.: 8533 AF XY: 0.262 AC XY: 35327AN XY: 134640
GnomAD3 exomes
AF:
AC:
62748
AN:
249216
Hom.:
AF XY:
AC XY:
35327
AN XY:
134640
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.262 AC: 373350AN: 1423676Hom.: 50794 Cov.: 23 AF XY: 0.266 AC XY: 188966AN XY: 710592
GnomAD4 exome
AF:
AC:
373350
AN:
1423676
Hom.:
Cov.:
23
AF XY:
AC XY:
188966
AN XY:
710592
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.224 AC: 34165AN: 152226Hom.: 4181 Cov.: 32 AF XY: 0.225 AC XY: 16753AN XY: 74436
GnomAD4 genome
AF:
AC:
34165
AN:
152226
Hom.:
Cov.:
32
AF XY:
AC XY:
16753
AN XY:
74436
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
924
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Familial episodic pain syndrome with predominantly upper body involvement Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 10, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at